FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL								
OMB Number:	3235-0104							
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

DI: : M. I. D.				of Event Requir nt (Month/Day/ 1021		3. Issuer Name and Ticker or Trading Symbol Evelo Biosciences, Inc. [ EVLO ]							
(Last) C/O EVELO BIO 620 MEMORIAL (Street) CAMBRIDGE (City)		(Middle)  02139  (Zip)					onship of Reporting Person(s) to Iss all applicable) Director Officer (give title below) Chief Commercial (	10% Owner Other (specif	/ below)		dividual or Joint/Grou	Original Filed (Month/Day/Year)  up Filing (Check Applicable Line) One Reporting Person Nore than One Reporting Person	
Table I - Non-Derivative Securities Beneficially Owned													
1. Title of Security (Instr. 4)					2. Amount Owned (In	of Securities Beneficially str. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		4. Nature of Indirect Beneficial Ownership (Instr. 5)				
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)													
Exp			2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlyi Security (Instr. 4)		ying Derivative	4. Conversor Exer	cise	5. Ownership Form: Direct (D) or Indirect (I)	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
			Date Exercisable	Expiration Date	Title		Amount or Number of Shares	Derivative Security		(Instr. 5)			

Explanation of Responses:

Remarks:

No securities are beneficially owned.

/s/ Daniel S. Char, Attorney-in-Fact for 06/14/2021

Mark D. Plinio

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## POWER OF ATTORNEY

With respect to holdings of and transactions in securities issued by Evelo Biosciences, Inc. (the "Company"), the undersigned hereby constitute

- 1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the United States Securities and Exchange Comm:
- 2. execute for and on behalf of the undersigned, Forms 3, 4, and 5 in accordance with Section 16 of the Securities Exchange Act of 1934, as
- 3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any sucl
- 4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of I The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assured this Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respecting the undersigned has caused this Power of Attorney to be executed as of this 6th day of June 2021.

Signature: /s/ Mark D. Plinio Print Name: Mark D. Plinio

Schedule A

Individuals Appointed as Attorney-in-Fact with Full Power of Substitution and Resubstitution Daniel S. Char

Xiaoli (Jacqueline) Liu